Cargando…

Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update

Macular edema (ME) is associated with various conditions; however, the main causes of ME are retinal vein occlusion (RVO) and diabetes. Laser photocoagulation, formerly the gold standard for the treatment of ME, has been replaced by anti-vascular endothelial growth factor (anti-VEGF) intravitreal in...

Descripción completa

Detalles Bibliográficos
Autores principales: Grzybowski, Andrzej, Markeviciute, Agne, Zemaitiene, Reda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619917/
https://www.ncbi.nlm.nih.gov/pubmed/34830582
http://dx.doi.org/10.3390/jcm10225300
_version_ 1784605100286672896
author Grzybowski, Andrzej
Markeviciute, Agne
Zemaitiene, Reda
author_facet Grzybowski, Andrzej
Markeviciute, Agne
Zemaitiene, Reda
author_sort Grzybowski, Andrzej
collection PubMed
description Macular edema (ME) is associated with various conditions; however, the main causes of ME are retinal vein occlusion (RVO) and diabetes. Laser photocoagulation, formerly the gold standard for the treatment of ME, has been replaced by anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections. Despite its efficiency, this treatment requires frequent injections to preserve the outcomes of anti-VEGF therapy, and as many patients do not sufficiently respond to the treatment, ME is typically a chronic condition that can lead to permanent visual impairment. Generalized recommendations for the treatment of ME are lacking, which highlights the importance of reviewing treatment approaches, including recent anti-VEGFs, intravitreal steroid implants, and subthreshold micropulse lasers. We reviewed relevant studies, emphasizing the articles published between 2019 and 2021 and using the following keywords: macular edema, diabetic macular edema, retinal vein occlusion, laser photocoagulation, anti-VEGF, and intravitreal injections. Our results revealed that a combination of different treatment methods may be beneficial in resistant cases. Additionally, artificial intelligence (AI) is likely to help select the best treatment option for patients in the near future.
format Online
Article
Text
id pubmed-8619917
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86199172021-11-27 Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update Grzybowski, Andrzej Markeviciute, Agne Zemaitiene, Reda J Clin Med Review Macular edema (ME) is associated with various conditions; however, the main causes of ME are retinal vein occlusion (RVO) and diabetes. Laser photocoagulation, formerly the gold standard for the treatment of ME, has been replaced by anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections. Despite its efficiency, this treatment requires frequent injections to preserve the outcomes of anti-VEGF therapy, and as many patients do not sufficiently respond to the treatment, ME is typically a chronic condition that can lead to permanent visual impairment. Generalized recommendations for the treatment of ME are lacking, which highlights the importance of reviewing treatment approaches, including recent anti-VEGFs, intravitreal steroid implants, and subthreshold micropulse lasers. We reviewed relevant studies, emphasizing the articles published between 2019 and 2021 and using the following keywords: macular edema, diabetic macular edema, retinal vein occlusion, laser photocoagulation, anti-VEGF, and intravitreal injections. Our results revealed that a combination of different treatment methods may be beneficial in resistant cases. Additionally, artificial intelligence (AI) is likely to help select the best treatment option for patients in the near future. MDPI 2021-11-15 /pmc/articles/PMC8619917/ /pubmed/34830582 http://dx.doi.org/10.3390/jcm10225300 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Grzybowski, Andrzej
Markeviciute, Agne
Zemaitiene, Reda
Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update
title Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update
title_full Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update
title_fullStr Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update
title_full_unstemmed Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update
title_short Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update
title_sort treatment of macular edema in vascular retinal diseases: a 2021 update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619917/
https://www.ncbi.nlm.nih.gov/pubmed/34830582
http://dx.doi.org/10.3390/jcm10225300
work_keys_str_mv AT grzybowskiandrzej treatmentofmacularedemainvascularretinaldiseasesa2021update
AT markeviciuteagne treatmentofmacularedemainvascularretinaldiseasesa2021update
AT zemaitienereda treatmentofmacularedemainvascularretinaldiseasesa2021update